Search

Search bills, members, committees and pages...

Sign In

H.R. 10164

U.S. House•In House Committee

Summary

H.R. 10164, the BEDROCK Act, was introduced in the House on Aug 27, 2026 by Rep. Robert Latta (R) with 1 co-sponsor. It was referred to Energy And Commerce, and last saw action on Aug 27, 2026: Referred to the House Committee on Energy and Commerce.

Record

Text

H.R. 10164 has 1 co-sponsor.

hb10164/introduced.txt
I
  119TH CONGRESS
  2D SESSION
  H. R. 10164
  To direct the Secretary of Commerce to promote competitiveness in biomanu-
  facturing in the United States, identify supply-chain and commercializa-
  tion vulnerabilities relating to critical biomanufacturing inputs and do-
  mestic production capacity, improve transparency regarding Federal proc-
  esses applicable to biomanufactured products, and for other purposes.
  IN THE HOUSE OF REPRESENTATIVES
  AUGUST 27, 2026
  Mr. LATTA (for himself and Mrs. DINGELL) introduced the following bill;
  which was referred to the Committee on Energy and Commerce
  A BILL
  To direct the Secretary of Commerce to promote competitive-
  ness in biomanufacturing in the United States, identify
  supply-chain and commercialization vulnerabilities relat-
  ing to critical biomanufacturing inputs and domestic pro-
  duction capacity, improve transparency regarding Fed-
  eral processes applicable to biomanufactured products,
  and for other purposes.
Be it enacted by the Senate and House of Representa-
  2 tives of the United States of America in Congress assembled,
ssavage on LAPJG3WLY3PROD with BILLS
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00001   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
   SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Biomanufacturing Ex-
  3 cellence, Domestic Resilience, Output, and Competitive
  4 Know-how Act’’ or the ‘‘BEDROCK Act’’.
   SEC. 2. ACTIVITIES RELATED TO PROMOTING COMPETI-
TIVENESS IN BIOMANUFACTURING IN THE
UNITED STATES.
(a) IN GENERAL.—Not later than 1 year after the
  9 date of the enactment of this Act, the Secretary shall des-
  10 ignate a senior official to—
(1) lead the activities of the Department of
Commerce relating to biomanufacturing and bio-
manufactured products in the United States;
(2) carry out the activities described in sub-
section (b); and
(3) promote commercial competitiveness with
respect to such biomanufacturing and biomanufac-
tured products.
(b) ACTIVITIES DESCRIBED.—The activities de-
  20 scribed in this subsection are the following:
(1) Identify the following:
(A) Any Federal process, resource, or pub-
licly available information relevant to promoting
commercial competitiveness with respect to bio-
ssavage on LAPJG3WLY3PROD with BILLS
manufacturing and biomanufactured products
in domestic and foreign commerce.
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00002   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(B) Any barrier to private sector invest-
ment in biomanufacturing, market adoption of
biomanufactured products, or domestic produc-
tion of such products, including barriers arising
from unclear, duplicative, or unpredictable Fed-
eral processes related to the commercialization
of such products.
(C) Any vulnerability, chokepoint, supplier
concentration, single point of failure, market
barrier, or other constraint affecting a supply
chain related to a critical biomanufacturing
input,  including  any  such  vulnerability,
chokepoint, supplier concentration, single point
of failure, market barrier, or other constraint
related to a foreign adversary or a foreign ad-
versary entity.
(D) Any opportunity for a private sector
entity or policymaker to strengthen domestic
production, supplier diversification, commer-
cialization, and supply chain resilience related
to biomanufacturing or biomanufactured prod-
ucts.
(E) The availability of domestic production
capacity, inputs, equipment, and other re-
ssavage on LAPJG3WLY3PROD with BILLS
sources related to the commercial manufac-
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00003   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
turing of biomanufactured products in the
United States, including with respect to the fol-
lowing:
(i) Amino acids.
(ii) Industrial enzymes.
(iii) Microbial strains.
(iv) Cell lines.
(v) Cell banks.
(vi) Bioreactors.
(vii) Single-use bioprocessing compo-
nents.
(2) Facilitate consultations, on a voluntary
basis, for participating non-Federal entities to pro-
mote commercial competitiveness with respect to bio-
manufacturing and biomanufactured products, in-
cluding consultations required pursuant to sub-
section (d)(3).
(3) Consult with the heads of relevant Federal
agencies, and any relevant agency point of contact,
including the Secretary of Health and Human Serv-
ices, acting through the Commissioner of Food and
Drugs, and the Administrator of the Environmental
Protection Agency, as the Secretary determines ap-
propriate, with respect to matters affecting the com-
ssavage on LAPJG3WLY3PROD with BILLS
petitiveness of biomanufacturing, supply-chain resil-
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00004   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
ience, and the commercial manufacturing of bio-
manufactured products.
(4) Maintain a publicly available web resource
that consolidates or provides links to publicly avail-
able Federal resources relevant to the commer-
cialization of biomanufactured products, as deter-
mined appropriate by the Secretary, including the
following information and resources:
(A) Any practice identified and made pub-
licly available under subsection (d).
(B) The report required under subsection
(e)(1).
(C) Any point of contact designated under
subsection (e)(3) or otherwise made publicly
available by a relevant Federal agency.
(5) Serve as a point of coordination for non-
Federal entities seeking publicly available informa-
tion related to a Federal process identified under
paragraph (1)(A), including by referring such enti-
ties to the appropriate Federal agency or point of
contact.
(c) ASSESSMENT.—
(1) IN GENERAL.—Not later than 1 year after
the date of the enactment of this Act, and every 2
ssavage on LAPJG3WLY3PROD with BILLS
years thereafter, the Secretary, acting through the
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00005   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
senior official designated pursuant to subsection (a),
shall conduct an assessment with respect to the fol-
lowing:
(A) The current and, to the extent prac-
ticable, reasonably foreseeable future avail-
ability of critical biomanufacturing inputs and
domestic production capacity related to bio-
manufacturing in the United States.
(B) The extent to which private sector en-
tities in the United States rely on foreign ad-
versaries or foreign adversary entities for crit-
ical biomanufacturing inputs or production ca-
pacity related to biomanufacturing.
(C) Any vulnerability, chokepoint, single
point of failure, supplier concentration, market
barrier, or other constraint impacting the ac-
cess of a private sector entity to critical bio-
manufacturing inputs or domestic production
capacity related to biomanufacturing.
(D) The availability of substitutes for crit-
ical biomanufacturing inputs in the United
States, including from other sources that are
not foreign adversaries or foreign adversary en-
tities.
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00006   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(E) Estimated lead times and economic or
operational barriers to reducing reliance by pri-
vate sector entities on a foreign adversary or a
foreign adversary entity for critical biomanufac-
turing inputs or production capacity related to
biomanufacturing.
(F) Any barrier identified under subsection
(b)(1)(B), including the following:
(i) Any Federal process for which a
review related to commercialization is di-
vided among multiple Federal agencies.
(ii) Any barrier arising from limited
access to shared pilot-scale and demonstra-
tion-scale manufacturing capacity.
(G) Any opportunity for domestic pro-
ducers and suppliers to expand the capacity of,
improve the reliability of, and diversify supply
chains for critical biomanufacturing inputs.
(H) Any impact on commerce and bio-
manufacturing in the United States if a vulner-
ability, chokepoint, single point of failure, sup-
plier concentration, market barrier, or other
constraint identified under subparagraph (C) is
not addressed, including any impact on relevant
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00007   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
domestic supply-chain resilience and access to
biomanufactured products.
(I) Biomanufacturing capacity located out-
side of the United States, including capacity at
contract manufacturing facilities and company-
owned facilities, and capacity owned or con-
trolled by foreign adversaries or foreign adver-
sary entities, to—
(i) compare such biomanufacturing
capacity with the biomanufacturing capac-
ity of the United States; and
(ii) assess the impact of such capacity
on domestic industry.
(2) PRIORITIZATION.—In conducting the as-
sessment under paragraph (1), the Secretary, acting
through the senior official designated pursuant to
subsection (a), shall prioritize the matters described
in such paragraph based on the following:
(A) The commercial significance of the rel-
evant affected critical biomanufacturing input
or production capacity.
(B) Potential consequences for commerce
in the United States.
(C) The extent of reliance on foreign ad-
ssavage on LAPJG3WLY3PROD with BILLS
versaries or foreign adversary entities.
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00008   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(D) Estimated lead times and barriers to
reducing such reliance.
(E) The availability of substitute sources.
(3) PRIORITIZED  ACTION  PLAN.—Based  on
each assessment under paragraph (1), the Secretary
shall prepare and include in any report submitted
and made publicly available under subsection (g) a
prioritized action plan that—
(A) ranks each supply-chain risk and com-
mercialization barrier identified in the assess-
ment by commercial significance and potential
consequence for commerce in the United States;
(B) identifies actions the Secretary may
take to improve supply-chain visibility, stake-
holder coordination, and access to information
related to the commercialization of biomanufac-
tured products;
(C) identifies existing Federal financial as-
sistance programs and other Federal resources
that may address any such supply-chain risk or
commercialization barrier;
(D) identifies any program or resource de-
scribed in subparagraph (C) that should be
added to the web resource maintained under
ssavage on LAPJG3WLY3PROD with BILLS
subsection (b)(4); and
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00009   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(E) identifies opportunities for the Sec-
retary to coordinate with relevant Federal agen-
cies and non-Federal entities to reduce such
risks and barriers.
(d) VOLUNTARY PRACTICES.—
(1) IN GENERAL.—Not later than 1 year after
the date of the enactment of this Act, and as the
Secretary determines appropriate thereafter, the
Secretary shall identify and make publicly available
industry-led, evidence-based, or widely accepted
practices related to the following:
(A) The commercialization of biomanufac-
turing processes and biomanufactured products.
(B) The readiness of biomanufacturing
processes or biomanufactured products for com-
mercial production.
(C) The reliability and operational consist-
ency of biomanufacturing processes and the
quality of biomanufactured products.
(D) Supplier qualification, supplier diver-
sification, and commercial supply chain risk
management for critical biomanufacturing in-
puts.
(E) The voluntary sharing of nonpropri-
ssavage on LAPJG3WLY3PROD with BILLS
etary information related to biomanufacturing
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00010   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
process and the supply chains for biomanufac-
turing processes or biomanufactured products
that is necessary to support commercialization
and commercial manufacturing, including the
secure and portable transfer of information that
a process originator elects to share with a man-
ufacturing partner, as appropriate.
(F) The protection of trade secrets, con-
fidential business information, and intellectual
property relating to biomanufacturing.
(G) The participation of small and me-
dium-sized businesses and manufacturers in
biomanufacturing.
(H) The use of biomanufactured products
in domestic and foreign commerce.
(I) The use of digital, computational, auto-
mated, or artificial intelligence tools in commer-
cial biomanufacturing to improve reliability, ef-
ficiency, product quality, and consistency.
(2) EXISTING  PRACTICES.—In  carrying out
paragraph (1), the Secretary shall—
(A) prioritize identifying existing practices,
including practices issued or maintained by in-
dustry-led organizations, and making such prac-
ssavage on LAPJG3WLY3PROD with BILLS
tices publicly available; and
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00011   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(B) avoid unnecessary duplication of such
practices.
(3) CONSULTATION.—In carrying out para-
graph (1), the Secretary shall consult with non-Fed-
eral entities, including the following:
(A) The following private sector entities:
(i) Manufacturers and suppliers of
critical biomanufacturing inputs.
(ii) Small and medium-sized busi-
nesses and manufacturers of biomanufac-
tured products.
(iii) Companies seeking to commer-
cialize, produce, or use biomanufactured
products.
(iv) Investors, accelerators, and other
entities involved in commercialization.
(B) State, local, Tribal, territorial, and re-
gional commerce or manufacturing organiza-
tions.
(C) Experts in commercial supply-chain re-
silience, manufacturing, and competitiveness.
(4) PRIORITIZATION OF UNITED STATES AND
TRUSTED STAKEHOLDERS.—In  carrying out para-
graph (3), the Secretary shall prioritize, to the ex-
ssavage on LAPJG3WLY3PROD with BILLS
tent practicable, input from non-Federal entities in
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00012   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
the United States and other stakeholders that are
neither foreign adversaries nor foreign adversary en-
tities.
(5) PUBLIC INPUT.—
(A) IN  GENERAL.—The  Secretary shall
provide at least 1 opportunity for the public to
submit input under this subsection.
(B) METHODS.—The Secretary may solicit
public input under this subsection through
making requests for information, workshops,
roundtables, meetings with non-Federal entities,
or any other means the Secretary determines
appropriate.
(e) FEDERAL COMMERCIALIZATION PATHWAY MAP;
  15 AGENCY POINTS OF CONTACT.—
(1) REPORT.—Not later than 1 year after the
date of the enactment of this Act, the Secretary, in
consultation with the heads of relevant Federal
agencies, shall submit to the appropriate congres-
sional committees and make publicly available a re-
port that identifies and maps any Federal process
that may apply to the commercialization of biomanu-
factured products and critical biomanufacturing in-
puts, as the Secretary determines appropriate.
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00013   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(2) CONTENTS.—The report required under
paragraph (1) shall do the following:
(A) Organize any Federal process identi-
fied and mapped under such paragraph by cat-
egory of biomanufactured product or critical
biomanufacturing input, as the Secretary deter-
mines appropriate.
(B) Identify the following:
(i) Any publicly available point of con-
tact for a Federal agency and any existing
public guidance related to any such Fed-
eral process.
(ii) Overlaps, gaps, ambiguities, and
timing or predictability concerns related to
any such Federal process.
(iii) Opportunities to improve the clar-
ity and predictability of, and reduce dupli-
cation among, any such Federal process.
(3) AGENCY POINTS OF CONTACT.—Not later
than 180 days after the date of the enactment of
this Act—
(A) the Secretary of Health and Human
Services, acting through the Commissioner of
Food and Drugs, shall—
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00014   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(i) designate a point of contact to as-
sist non-Federal entities in identifying pub-
licly available information related to any
process of the Food and Drug Administra-
tion that may apply to biomanufactured
products or critical biomanufacturing in-
puts; and
(ii) ensure such point of contact co-
ordinates, as appropriate, with relevant
components of the Food and Drug Admin-
istration in carrying out clause (i); and
(B) the Administrator of the Environ-
mental Protection Agency shall designate a
point of contact to assist non-Federal entities in
identifying publicly available information re-
lated to laws administered by the Administrator
of the Environmental Protection Agency that
may apply to biomanufactured products or crit-
ical biomanufacturing inputs.
(4)  INTEGRATION  WITH  EXISTING        RE-
SOURCES.—
(A) IN GENERAL.—In carrying out para-
graphs (1) and (2), the Secretary may incor-
porate or rely on a substantially similar existing
ssavage on LAPJG3WLY3PROD with BILLS
Federal resource, report, assessment, map, or
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00015   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
other activity if the Secretary determines that it
substantially addresses the applicable require-
ment.
(B) INCLUSION IN REPORT.—If the Sec-
retary incorporates or relies on a substantially
similar existing Federal resource, report, as-
sessment, map, or other activity under subpara-
graph (A), the Secretary shall include in the re-
port required under paragraph (1) the fol-
lowing:
(i) An identification of the resource,
report, assessment, map, or other activity.
(ii) An explanation of how the re-
source, report, assessment, map, or other
activity addresses the applicable require-
ment.
(5) UPDATES.—The Secretary shall update the
report required under paragraph (1) to reflect any
material change to any Federal process described in
such paragraph, as the Secretary determines appro-
priate.
(f) PROTECTION OF INFORMATION.—
(1) IN GENERAL.—The Secretary may not pub-
licly disclose any nonpublic information voluntarily
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00016   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
submitted by a non-Federal entity under this section
that—
(A) constitutes a trade secret or confiden-
tial business information; or
(B) is sensitive supply-chain vulnerability
information.
(2) EXEMPTION FROM DISCLOSURE.—Informa-
tion described in paragraph (1) shall be exempt from
disclosure under section 552(b)(3) of title 5, United
States Code.
(3) IDENTIFICATION AND DETERMINATION.—
(A) IN GENERAL.—The Secretary shall es-
tablish a process for a non-Federal entity that
voluntarily submits information under this sec-
tion to identify whether the entity considers
such information to be nonpublic information
described in paragraph (1).
(B) DETERMINATION.—If a non-Federal
entity makes an identification under the process
required by subparagraph (A), with respect to
information voluntarily submitted under this
section by such entity, the Secretary shall de-
termine whether such information is nonpublic
information described in paragraph (1).
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00017   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(C) TREATMENT  PENDING  DETERMINA-
TION.—The Secretary may not publicly disclose
any information with respect to which a non-
Federal entity makes an identification under
paragraph (3)(A) unless the Secretary has de-
termined such information is not nonpublic in-
formation described in paragraph (1).
(g) REPORTS.—
(1) IN GENERAL.—Not later than 1 year after
the date of the enactment of this Act, and every 2
years thereafter, the Secretary, acting through the
senior official designated pursuant to subsection (a),
shall submit to the appropriate congressional com-
mittees, and make publicly available on a website of
the Department of Commerce, a report that includes
the following:
(A) A summary of any action carried out
by the Secretary under this section.
(B) Any assessment conducted under sub-
section (c).
(C) Any prioritized action plan prepared
under paragraph (3) of such subsection.
(D) A summary of any practices identified
and made publicly available under subsection
ssavage on LAPJG3WLY3PROD with BILLS
(d).
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00018   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
(E) Any updates related to the report re-
quired under subsection (e)(1).
(2) NONPUBLIC ANNEX.—The Secretary, acting
through the senior official designated pursuant to
subsection (a), may submit to the appropriate con-
gressional committees a nonpublic annex to a report
required under paragraph (1) that includes non-
public information described in subsection (f)(1).
(h) TERMINATION.—The requirements under sub-
  10 sections (a) through (e) and subsection (g) shall terminate
  11 on the date that is 5 years after the date of the enactment
  12 of this Act.
(i) DEFINITIONS.—In this section:
(1) APPROPRIATE  CONGRESSIONAL  COMMIT-
TEES.—The  term ‘‘appropriate congressional com-
mittees’’ means—
(A) the Committee on Energy and Com-
merce of the House of Representatives; and
(B) the Committee on Commerce, Science,
and Transportation of the Senate.
(2) BIOMANUFACTURED PRODUCT.—The term
‘‘biomanufactured product’’ means a commercial
good, material, chemical, protein, component, indus-
trial input, or other product or substance in com-
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00019   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
merce that is produced, processed, purified, or trans-
formed through biomanufacturing.
(3)        BIOMANUFACTURING.—The  term    ‘‘bio-
manufacturing’’ means the use of biological systems,
including cells, cell-free systems, enzymes, or biomol-
ecules, in manufacturing processes to produce, proc-
ess, or transform commercial goods, materials,
chemicals, proteins, components, industrial inputs,
or other products or substances in commerce.
(4) CRITICAL  BIOMANUFACTURING  INPUT.—
The term ‘‘critical biomanufacturing input’’ means
an input, material, reagent, item of equipment, or
software used in biomanufacturing that is commer-
cially significant to biomanufacturing in the United
States and subject to supply-chain risk, such as sup-
plier concentration, reliance on a foreign adversary
or foreign adversary entity, limited substitutes, or
long lead times.
(5) FOREIGN ADVERSARY.—The term ‘‘foreign
adversary’’ means a foreign government or foreign
non-government person identified as a foreign adver-
sary under section 791.4 of title 15, Code of Federal
Regulations, or any successor regulation.
(6) FOREIGN ADVERSARY ENTITY.—The term
ssavage on LAPJG3WLY3PROD with BILLS
‘‘foreign adversary entity’’ has the meaning given
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00020   Fmt 6652   Sfmt 6201   E:\BILLS\H10164.IH   H10164
the term ‘‘person owned by, controlled by, or subject
to the jurisdiction or direction of a foreign adver-
sary’’ in section 791.2 of title 15, Code of Federal
Regulations, or any successor regulation.
(7) NON-FEDERAL ENTITY.—The term ‘‘non-
Federal entity’’ means a State, local, Tribal, or ter-
ritorial government, nonprofit organization, technical
organization, industry association, commerce or
manufacturing organization, private sector entity, or
other stakeholder.
(8) SECRETARY.—The term ‘‘Secretary’’ means
the Secretary of Commerce.
(9) SENSITIVE SUPPLY-CHAIN VULNERABILITY
INFORMATION.—The  term ‘‘sensitive supply-chain
vulnerability information’’ means nonpublic informa-
tion with respect to which the public disclosure of
such nonpublic information could be reasonably ex-
pected  to   reveal  a    vulnerability,  dependency,
chokepoint, single point of failure, supplier con-
centration, or other weakness in a supply chain rel-
evant to biomanufacturing in the United States.
  Æ
ssavage on LAPJG3WLY3PROD with BILLS
  •HR 10164 IH
  VerDate Sep 11 2014   20:48 Aug 27, 2026   Jkt 069200   PO 00000   Frm 00021   Fmt 6652   Sfmt 6301   E:\BILLS\H10164.IH   H10164

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2026-08-27
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To direct the Secretary of Commerce to promote competitiveness in biomanufacturing in the United States, identify supply-chain and commercialization vulnerabilities relating to critical biomanufacturing inputs and domestic production capacity, improve transparency regarding Federal processes applicable to biomanufactured products, and for other purposes.

Sponsors

Rep. Robert Latta (R) sponsors H.R. 10164, and 1 member has co-sponsored it from the day it was introduced.

Committees

H.R. 10164 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Aug 27, 2026 · 1,636 Bills

Actions

H.R. 10164 has taken 2 actions since Aug 27, 2026.

ChamberAction
Aug 27, 2026
House
Introduced in House
Aug 27, 2026
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 10164 has not gone to a roll call.

Titles

H.R. 10164 goes by 4 titles, 2 of them short titles.

  • BEDROCK Act — Display Title
  • BEDROCK Act — Short Title(s) as Introduced
  • Biomanufacturing Excellence, Domestic Resilience, Output, and Competitive Know-how Act — Short Title(s) as Introduced
  • To direct the Secretary of Commerce to promote competitiveness in biomanufacturing in the United States, identify supply-chain and commercialization vulnerabilities relating to critical biomanufacturing inputs and domestic production capacity, improve transparency regarding Federal processes applicable to biomanufactured products, and for other purposes. — Official Title as Introduced

Classification

The Congressional Research Service files H.R. 10164 under Health, one of its 31 policy areas.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 10164’s is Health.

hr10164/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Constitutional authority

The clause the sponsor cites as Congress’s power to enact H.R. 10164, as entered in the Congressional Record.

[Congressional Record Volume 172, Number 136 (Thursday, August 27, 2026)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. LATTA:H.R. 10164.Congress has the power to enact this legislation pursuantto the following:clause 3 of section 8 of article I of the Constitution[Page H5258]

Source: congress.gov · legiscan.com